CHICAGO, July 16, 2025 /PRNewswire/ -- Amphix Bio, a pre-clinical stage company developing a new therapeutic modality for regenerative medicine, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate AMFX-200 for treatment of acute...
Hence then, the article about amphix bio receives fda orphan drug designation for neural regeneration therapeutic to treat acute spinal cord injury was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Amphix Bio receives FDA Orphan Drug Designation for neural regeneration therapeutic to treat acute spinal cord injury )
Also on site :
- 'The chances of you living 50 years are very small': Theoretical physicist explains why humanity likely won't survive to see all the forces unified
- The Strokes End Coachella Performance With Video Montage Condemning U.S. and Israeli Bombings in Iran and Gaza
- FBI, DOJ scrambling to rebuild after being depleted by resignations and firings